News Headline Summary

Sarepta Therapeutics (SRPT) files first patent application "Multiple Exon Skipping Compositions for DMD" in an nearly move to protect the Eteplirsen franchise

Reaction details (16:37)

- No immediate reaction seen in Co. shares, trades USD 36.55 last. (-2.97%)

25 Jul 2013 - 16:35 - Equities - Source: Hammerstone

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: